Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 1.74 CAD -1.69% Market Closed
Market Cap: 80m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

Intrinsic Value

The intrinsic value of one TH stock under the Base Case scenario is 7.66 CAD. Compared to the current market price of 1.74 CAD, Theratechnologies Inc is Undervalued by 77%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TH Intrinsic Value
7.66 CAD
Undervaluation 77%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Theratechnologies Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TH?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Theratechnologies Inc

Provide an overview of the primary business activities
of Theratechnologies Inc.

What unique competitive advantages
does Theratechnologies Inc hold over its rivals?

What risks and challenges
does Theratechnologies Inc face in the near future?

Summarize the latest earnings call
of Theratechnologies Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Theratechnologies Inc.

Provide P/S
for Theratechnologies Inc.

Provide P/E
for Theratechnologies Inc.

Provide P/OCF
for Theratechnologies Inc.

Provide P/FCFE
for Theratechnologies Inc.

Provide P/B
for Theratechnologies Inc.

Provide EV/S
for Theratechnologies Inc.

Provide EV/GP
for Theratechnologies Inc.

Provide EV/EBITDA
for Theratechnologies Inc.

Provide EV/EBIT
for Theratechnologies Inc.

Provide EV/OCF
for Theratechnologies Inc.

Provide EV/FCFF
for Theratechnologies Inc.

Provide EV/IC
for Theratechnologies Inc.

Show me price targets
for Theratechnologies Inc made by professional analysts.

What are the Revenue projections
for Theratechnologies Inc?

How accurate were the past Revenue estimates
for Theratechnologies Inc?

What are the Net Income projections
for Theratechnologies Inc?

How accurate were the past Net Income estimates
for Theratechnologies Inc?

What are the EPS projections
for Theratechnologies Inc?

How accurate were the past EPS estimates
for Theratechnologies Inc?

What are the EBIT projections
for Theratechnologies Inc?

How accurate were the past EBIT estimates
for Theratechnologies Inc?

Compare the revenue forecasts
for Theratechnologies Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Theratechnologies Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Theratechnologies Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Theratechnologies Inc compared to its peers.

Compare the P/E ratios
of Theratechnologies Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Theratechnologies Inc with its peers.

Analyze the financial leverage
of Theratechnologies Inc compared to its main competitors.

Show all profitability ratios
for Theratechnologies Inc.

Provide ROE
for Theratechnologies Inc.

Provide ROA
for Theratechnologies Inc.

Provide ROIC
for Theratechnologies Inc.

Provide ROCE
for Theratechnologies Inc.

Provide Gross Margin
for Theratechnologies Inc.

Provide Operating Margin
for Theratechnologies Inc.

Provide Net Margin
for Theratechnologies Inc.

Provide FCF Margin
for Theratechnologies Inc.

Show all solvency ratios
for Theratechnologies Inc.

Provide D/E Ratio
for Theratechnologies Inc.

Provide D/A Ratio
for Theratechnologies Inc.

Provide Interest Coverage Ratio
for Theratechnologies Inc.

Provide Altman Z-Score Ratio
for Theratechnologies Inc.

Provide Quick Ratio
for Theratechnologies Inc.

Provide Current Ratio
for Theratechnologies Inc.

Provide Cash Ratio
for Theratechnologies Inc.

What is the historical Revenue growth
over the last 5 years for Theratechnologies Inc?

What is the historical Net Income growth
over the last 5 years for Theratechnologies Inc?

What is the current Free Cash Flow
of Theratechnologies Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Theratechnologies Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Theratechnologies Inc

Current Assets 57.2m
Cash & Short-Term Investments 38.9m
Receivables 10.7m
Other Current Assets 7.7m
Non-Current Assets 12.5m
PP&E 788k
Intangibles 11.4m
Other Non-Current Assets 259k
Current Liabilities 52.9m
Accounts Payable 23.8m
Other Current Liabilities 29.1m
Non-Current Liabilities 36.5m
Long-Term Debt 36.5m
Other Non-Current Liabilities 18k
Efficiency

Earnings Waterfall
Theratechnologies Inc

Revenue
84.3m USD
Cost of Revenue
-19.4m USD
Gross Profit
64.9m USD
Operating Expenses
-55.9m USD
Operating Income
9m USD
Other Expenses
-12.2m USD
Net Income
-3.2m USD

Free Cash Flow Analysis
Theratechnologies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, Theratechnologies reported strong financial results, with net sales rising 8.4% to $22.6 million. EGRIFTA SV sales notably surged by 27% year-over-year to $16.7 million, driven by robust patient enrollment. However, Trogarzo sales fell to $5.9 million due to competitive pressures. Adjusted EBITDA reached $7.2 million, prompting a revenue guidance revision to $83-$85 million and EBITDA guidance increased to $17-$19 million for 2024. Despite expected supply constraints impacting Q4 sales, strategic cost management and a strong cash position of $39 million positions the company for sustained growth.

What is Earnings Call?
Fundamental Scores

TH Profitability Score
Profitability Due Diligence

Theratechnologies Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROIC
ROE is Increasing
51/100
Profitability
Score

Theratechnologies Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

TH Solvency Score
Solvency Due Diligence

Theratechnologies Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
35/100
Solvency
Score

Theratechnologies Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TH Price Targets Summary
Theratechnologies Inc

Wall Street analysts forecast TH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TH is 8.16 CAD with a low forecast of 8.08 CAD and a high forecast of 8.4 CAD.

Lowest
Price Target
8.08 CAD
364% Upside
Average
Price Target
8.16 CAD
369% Upside
Highest
Price Target
8.4 CAD
383% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TH?

Click here to dive deeper.

Dividends

Theratechnologies Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Theratechnologies Inc Logo
Theratechnologies Inc

Country

Canada

Industry

Biotechnology

Market Cap

80m CAD

Dividend Yield

0%

Description

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

Contact

QUEBEC
MONTREAL
2015 Peel Street, 5Th Floor
+5143367800.0
www.theratech.com

IPO

1993-12-21

Employees

87

Officers

President, CEO & Director
Mr. Paul LĂ©vesque
Senior VP & CFO
Mr. Philippe Dubuc M.B.A., MBA
General Counsel & Corporate Secretary
Mr. Jocelyn Lafond L.L.M., LL.B.
Senior VP & Chief Medical Officer
Dr. Christian Marsolais Ph.D.
Global Commercial Officer
Mr. John Leasure
Vice President of Human Resources
Hon. Andre Dupras M.Sc.

See Also

Discover More
What is the Intrinsic Value of one TH stock?

The intrinsic value of one TH stock under the Base Case scenario is 7.66 CAD.

Is TH stock undervalued or overvalued?

Compared to the current market price of 1.74 CAD, Theratechnologies Inc is Undervalued by 77%.

Back to Top